IDDM患者外周血总T淋巴细胞及其亚群的观察

用单克隆抗体技术测定了16例病程在1.5年以上的IDDM患者和18例正常人外周血总T淋巴细胞及其亚群,显示两组间OKT_3、OKT_4、OKT_8、OKT_4/OKT_8差异均无显著性。提示病程超过1.5年的IDDM者的细胞免疫功能已趋于稳定。且16例IDDM患者的总T淋巴细胞及其亚群在胰岛移植前、后差异也没有显著性,认为目前国内应用的胡氏胰岛组织培养法有利于降低胰岛组织对人IDDM受体的免疫原性。     

A two-label microfluorometric analysis of the expression of OKT5 and Leu 2a antigens on peripheral blood lymphocytes in patients with multiple sclerosis

Four patients with relapsing-remitting multiple sclerosis (MS) and one control were evaluated serially over a 10-week interval. Peripheral blood lymphocyte (PBL) subsets were enumerated using a double labelling technique, OKT5 and anti-Leu 2a monoclonal antibodies, and FACS IV analysis. Results were correlated with clinically assessed disease activity. Two subsets were identified. Subset 1 is characterized by cells positive for Leu 2a and either weakly positive or negative for OKT5 . Subset 2 was positive for both. Subset 1 was constantly present in both patients and controls while subset 2 was variable in presence and in size. No associations between these subsets and disease activity were made in this preliminary study, however, no acute relapses occurred in this interval. It is postulated that the reason for the differences in results of studies attempting to correlate disease activity with PBL phenotypes as assessed by different monoclonal antibodies may be the result of the suppressor/cytotoxic cell subpopulation being nonhomogeneous for the expression of various cell surface antigens. The technique of multiple labelling of lymphocytes may be useful in defining subsets which correlate more closely with disease activity.     

肾移植术后应用OKT3的临床观察与护理

通过对36例肾移植术后应用OKT3的临床观察和护理，总结了OKT3在预防性使用和治疗性使用后可能出现的不良反应、症状特征、相应的处理方法和护理措施。指出严格有效的监护是防治并发症发生的重要手段。     

New developments in immunosuppressive therapy for heart transplantation

Background: Heart transplantation is a well-established therapeutic option for many patients with end-stage heart disease. A major challenge in heart transplantation today is providing effective immunosuppression to prevent graft rejection while minimizing the many adverse effects of currently available therapies. Objective: To systematically review current immunosuppressive treatment strategies after heart transplantation and to review emerging drugs in various stages of development. Methods: A comprehensive literature review was performed using the online PubMed and Pharmaprojects databases. Results/conclusions: This article gives an overview of the immunosuppressive agents in current use, with a detailed review of emerging drugs with novel therapeutic targets.     

Reversal of acute glomerular renal allograft rejection: a possible effect of OKT3

A major cause of renal allograft loss is glomerulovascular rejection. This case report is about an episode of histologically proven acute glomerular rejection that was successfully reversed. Monoclonal antibody OKT3 may have been the effective agent.     

The risk of infection following OKT3 and antilymphocyte globulin treatment for renal transplant rejection: results of a single center prospectively randomized trial

Some 43 of 60 (72%) renal allograft recipients who were prospectively randomized to receive either OKT3 monoclonal antibody (n = 30) or ALG (antilymphocyte globulin) polyclonal antibody (n = 30) for steroid-resistant rejection suffered from infection, 25 (83%) following OKT3 and 18 (60%) following ALG treatment (P < 0.05). Clinically evident herpes infection was most frequently seen (9 and 7, respectively), followed by pneumonia (6 and 1, respectively P < 0.05), urinary tract infection and wound infection (2 of each in both groups) fungal (Candida) and multibacterial infections. One patient died in each group due to cytomegalovirus (CMV) pneumonia, giving a mortality of 4.3% in each group. Actuarial 1-year graft and patient survival rates were 80% and 97% in both groups, respectively. It is concluded that ALG and OKT3 are equally effective in renal allograft rejection resistant to steroid treatment, however, the risk of infection appears to be higher with OKT3.     

晚期宫颈癌和CLT患者外周血T细胞亚群检测结果分析

应用OKT单抗对20例初诊晚期宫颈癌和15例慢性淋巴性甲状腺炎(CLT)患者的外周血T淋巴细胞亚群检测结果表明,与正常人相比,宫颈癌患者OKT_3和OKT_4细胞均明显减少,OKT_8细胞明显增多,OKT_4/OKT_8比值显著降低,CLT患者OKT_3和OKT_8细胞减少,OKT_4/OKT_8比值显著升高。本研究表明宫颈癌和CLT均有T细胞亚群的紊乱,提示OKT_4/OKT_8比值的相对平衡是决定机体免疫状态和免疫反应水平的中心环节。     

半剂量OKT3能逆转移植肾耐激素型急性排异

目的：了解半剂量ＯＫＴ３能否逆转移移植肾耐激素型急性排异（ＳＲ－ＡＲ）。方法：对发生ＳＲ－ＡＲ的肾移植受者，采用半剂量ＯＫＴ３治疗，并与全剂量ＯＫＴ３组对照，观察两组的ＳＲ－ＡＲ的逆转率及并发症发生率。结果：半剂量ＯＫＴ３组ＳＲ－ＡＲ逆转率为８８．９％，ＣＭＶ病发生率为３８．９％、发热６６．７％、寒颤２２．２％、恶心、１６．７％、腹泻１１．１％，与全剂量ＯＫＴ３组相比，两组ＳＲ－ＡＲ逆转率及上中种     

Unusual Nonimmunoglobulin-Containing Inclusions in a Case of Follicular Large Cell Lymphoma

Intracytoplasmic inclusion bodies were found in a case of follicular large cell lymphoma. They did not react with anti-immunoglobulin antisera and showed no enzyme reactivity. On electron microscopy the inclusions consisted of loosely packed fibrillar material not surrounded by a membrane or by rough endoplasmic reticulum. They were found only in the large lymphomatous cells. Immunocytochemistry showed a reactivity of these cells with anti-HLA-Dr and the OKT10 monoclonal antibodies.

The nature of the inclusions remains unknown. They differ significantly from those described in the literature in cases of B-cell lymphoproliferative disorders.